USPTO Guidance on AI Inventorship
Recent USPTO guidance on AI-assisted inventions reinforces that artificial intelligence cannot be named as an inventor, while human contributors who meaningfully shape conception may still qualify. For AI patent review, applications must clearly identify the human intellectual contribution behind each claimed invention, especially where machine learning models generate candidates, optimize parameters, or analyze data. Reviewers should examine inventorship statements, prosecution history, and technical records to ensure claimed subject matter reflects genuine human direction rather than autonomous machine output.
Also worth reading: How Does AI-Assisted Patent Inventorship Guidance Define Human Contribution? · How Should AI Patent Inventorship Documentation Be Prepared? · How Can Companies Manage AI Patent Inventorship Risk in 2025?
For companies and counsel, the practical effect is a stronger need for documentation, inventor interviews, and careful claim drafting before filing. Patent review should assess whether prompts, training choices, experimental design, and selection of AI-generated results demonstrate sufficient human control. Where inventorship is uncertain, teams may consider trade secret protection, narrower claims, or additional validation. Ultimately, the updates do not bar AI-assisted patents, but they raise the evidentiary standard for showing that a natural person conceived the invention.
Human Contribution Requirements Explained
USPTO updates clarify that artificial intelligence cannot be named as an inventor, so every patent application must identify a human who made a significant contribution to conception. For AI patent review, this means examiners will look beyond polished outputs and ask whether the human role was substantive rather than routine assistance. In fields such as AI drug discovery, teams should align claims with documented human decisions about targets, models, data, and validation. The guidance also reinforces that inventorship is assessed claim by claim, making broad or vague claims riskier when AI generated much of the technical content.
Practitioners should therefore build prosecution files that show human problem framing, experimental design, interpretation of results, and iterative claim refinement. Where training data or model details are competitively sensitive, trade secret protection may complement patents rather than replace them. The overall message is that AI can be a powerful tool, but patentability still depends on demonstrable human ingenuity. Careful records, precise claim drafting, and early inventorship analysis can reduce rejection risk and strengthen enforceable rights.
AI-Assisted Drug Discovery Patents
USPTO inventorship updates clarify that AI cannot be named as an inventor, but human contributors who meaningfully shape AI-assisted discoveries may still qualify. For AI patent review, this means examiners and applicants should document human conception, experimental design, data selection, prompt engineering, and validation rather than relying on model output alone. The guidance reduces uncertainty for drug discovery teams using generative models to identify compounds, optimize leads, or predict properties, while emphasizing that patentability still depends on human intellectual contribution. It also encourages careful claim drafting around methods, systems, and therapeutic uses where human direction is evident.
Practically, organizations should align inventorship analysis with trade secret and patent strategies, maintain records of human decisions, and assess whether AI-generated results are sufficiently directed by people. The updates may improve optimism for AI-based applications, yet they do not create a special standard for machine-made inventions. Patent review should therefore focus on evidence of human problem framing, selection, and refinement, ensuring claims reflect genuine inventive contribution rather than automated discovery alone.
Pre-Examination Search Pilot Tools
The USPTO’s revised inventorship guidance keeps the focus on human contribution, even when AI tools help generate ideas, data, or claim language. For AI patent review, reviewers should not treat an AI system as an inventor, but should examine whether a natural person made a significant contribution to conception and whether the application clearly identifies that human role. Strong records matter because prompts, experiments, model outputs, and human edits can show who directed the invention and how final claims reflect human judgment. This matters in AI drug discovery.
The updates also encourage a careful balance between patent protection and trade secret strategy. Reviewers should look for disclosures that explain the invention without revealing unnecessary proprietary model details, while still satisfying enablement and written description requirements. For teams using AI, the practical takeaway is to document human decision-making early, align claims with actual inventive contributions, and avoid overclaiming AI-generated results. Done well, AI-assisted applications can remain patentable and defensible, with review focused on clarity, human authorship, and technical quality.
Eligibility and Claim Strategy
The USPTO's revised inventorship guidance for AI-assisted inventions clarifies that artificial intelligence cannot be named as an inventor, but human contributors who meaningfully direct, prompt, or refine AI outputs may still qualify. This matters for AI patent review because applications must now clearly document human conception and contribution throughout the inventive process. Reviewers should assess whether claims reflect genuine human inventive input rather than machine-generated output alone, ensuring eligibility standards remain consistent with established patent law. Careful review of these factors can reduce rejection risk and improve application quality.
For organizations, the updates encourage stronger record-keeping around prompts, model selection, and human refinement across the development cycle. Patent and trade secret strategies may shift as teams decide what to patent versus protect as confidential information. Ultimately, the guidance aims to preserve human inventorship while accommodating AI tools, helping applicants navigate eligibility and claim strategy with greater confidence and clarity.
AI Inventorship Guidance Comparison
| Update Area | What It Means | AI Patent Review Impact |
|---|---|---|
| Human inventorship | AI cannot be sole inventor; a natural person must contribute | Review claims for human contribution |
| AI-assisted inventions | Patentable when a human significantly contributes | Assess disclosure and inventorship |
| Documentation | Record the human role in conception | Strengthen prosecution support |
| Strategy | Combine patents with trade secrets | Align review with portfolio goals |